Targeting a host process as an antiviral approach against dengue virus

Gubler, 2006, Flaviviruses, 1153 Kuno, 1998, Phylogeny of the genus Flavivirus, J. Virol., 72, 73, 10.1128/JVI.72.1.73-83.1998 Halstead, 2007, Dengue, Lancet, 370, 1644, 10.1016/S0140-6736(07)61687-0 Libraty, 2002, High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever, J. Infect. Dis., 186, 1165, 10.1086/343813 Vaughn, 2000, Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity, J. Infect. Dis., 181, 2, 10.1086/315215 Halstead, 2008, Dengue: overview and history, 1 Farrar, 2008, Clinical features of dengue, 171 WHO, 2004 WHO, 2009 Cho Min, 2000, Assessment of dengue hemorrhagic fever in Myanmar, Southeast Asian J. Trop. Med. Public Health, 31, 636 Meltzer, 1998, Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994, Am. J. Trop. Med. Hyg., 59, 265, 10.4269/ajtmh.1998.59.265 Wills, 2008, Managment of dengue, 193 Whitehead, 2007, Prospects for a dengue virus vaccine, Nat. Rev. Microbiol., 5, 518, 10.1038/nrmicro1690 Damonte, 2004, Prospects for the therapy and prevention of dengue virus infections, Adv. Virus Res., 63, 239, 10.1016/S0065-3527(04)63004-1 Li, 2008, Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins, J. Med. Chem., 51, 4660, 10.1021/jm800412d Perera, 2008, Closing the door on flaviviruses: entry as a target for antiviral drug design, Antiviral Res., 80, 11, 10.1016/j.antiviral.2008.05.004 Malet, 2008, The flavivirus polymerase as a target for drug discovery, Antiviral Res., 80, 23, 10.1016/j.antiviral.2008.06.007 Sampath, 2009, Molecular targets for flavivirus drug discovery, Antiviral Res., 81, 6, 10.1016/j.antiviral.2008.08.004 Yin, 2009, An adenosine nucleoside inhibitor of dengue virus, Proc. Natl. Acad. Sci. U. S. A., 106, 20435, 10.1073/pnas.0907010106 Lescar, 2008, Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target, Antiviral Res., 80, 94, 10.1016/j.antiviral.2008.07.001 Balsitis, 2010, Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification, PLoS Pathog., 6, e1000790, 10.1371/journal.ppat.1000790 Williams, 2009, A mouse model for studying dengue virus pathogenesis and immune response, Ann. N. Y. Acad. Sci., 1171, E12, 10.1111/j.1749-6632.2009.05057.x Zellweger, 2010, Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease, Cell Host Microbe, 7, 128, 10.1016/j.chom.2010.01.004 Pollock, 2010, Uptake and trafficking of liposomes to the endoplasmic reticulum, FASEB J., 10.1096/fj.09-145755 Sessions, 2009, Discovery of insect and human dengue virus host factors, Nature, 458, 1047, 10.1038/nature07967 Limjindaporn, 2009, Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production, Biochem. Biophys. Res. Commun., 379, 196, 10.1016/j.bbrc.2008.12.070 Barradas, 2008, Synthesis and antiviral activity of azoles obtained from carbohydrates, Carbohydr. Res., 343, 2468, 10.1016/j.carres.2008.06.028 Sepúlveda, 2008, Synthesis and evaluation of N-substituted acridones as antiviral agents against haemorrhagic fever viruses, Antivir. Chem. Chemother., 19, 41, 10.1177/095632020801900106 Zhang, 2009, Antiviral activity of geneticin against dengue virus, Antiviral Res., 83, 21, 10.1016/j.antiviral.2009.02.204 Aman, 2009, Development of a broad-spectrum antiviral with activity against Ebola virus, Antiviral Res., 83, 245, 10.1016/j.antiviral.2009.06.001 Datema, 1984, On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus, Arch. Virol., 81, 25, 10.1007/BF01309294 Tan, 1991, Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin. Structure–activity relationships, J. Biol. Chem., 266, 14504, 10.1016/S0021-9258(18)98715-6 Durantel, 2001, Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus, J. Virol., 75, 8987, 10.1128/JVI.75.19.8987-8998.2001 Alonzi, 2008, Glucosylated free oligosaccharides are biomarkers of endoplasmic reticulum alpha-glucosidase inhibition, Biochem. J., 409, 571, 10.1042/BJ20070748 Pavlovic, 2003, The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives, Proc. Natl. Acad. Sci. U. S. A., 100, 6104, 10.1073/pnas.1031527100 Steinmann, 2007, Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus, Hepatology, 46, 330, 10.1002/hep.21686 Zitzmann, 1999, Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents, Proc. Natl. Acad. Sci. U. S. A., 96, 11878, 10.1073/pnas.96.21.11878 Lu, 2003, The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture, J. Virol., 77, 11933, 10.1128/JVI.77.22.11933-11940.2003 Mehta, 2001, Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications, Hepatology, 33, 1488, 10.1053/jhep.2001.25103 Chang, 2009, Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses, Antimicrob. Agents Chemother., 53, 1501, 10.1128/AAC.01457-08 Gu, 2007, Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus, Antivir. Chem. Chemother., 18, 49, 10.1177/095632020701800105 Tan, 1994, Introduction of oxygen into the alkyl chain of N-decyl-dNM decreases lipophilicity and results in increased retention of glucose residues on N-linked oligosaccharides, Glycobiology, 4, 141, 10.1093/glycob/4.2.141 Liang, 2006, Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis, Chembiochem, 7, 165, 10.1002/cbic.200500321 Whitby, 2005, Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo, J. Virol., 79, 8698, 10.1128/JVI.79.14.8698-8706.2005 Courageot, 2000, Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum, J. Virol., 74, 564, 10.1128/JVI.74.1.564-572.2000 Yauch, 2008, Mouse models of dengue virus infection and disease, Antiviral Res., 80, 87, 10.1016/j.antiviral.2008.06.010 Schul, 2007, A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs, J. Infect. Dis., 195, 665, 10.1086/511310 Malinoski, 1990, Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys, Antiviral Res., 13, 139, 10.1016/0166-3542(90)90029-7 Durantel, 2009, Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection, Curr. Opin. Investig. Drugs, 10, 860 Fleet, 1988, Inhibition of HIV replication by amino-sugar derivatives, FEBS Lett., 237, 128, 10.1016/0014-5793(88)80185-6 Ratner, 1993, Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs, AIDS Res. Hum. Retroviruses, 9, 291, 10.1089/aid.1993.9.291 Tierney, 1995, The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases, J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 10, 549, 10.1097/00042560-199512050-00008 Fischl, 1994, The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3, J. Acquir. Immune. Defic. Syndr., 7, 139 Pollock, 2008, N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery, AIDS, 22, 1961, 10.1097/QAD.0b013e32830efd96 Murray, 2008, Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis, Nat. Rev. Microbiol., 6, 699, 10.1038/nrmicro1928 Rawlings, 2009, Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors, Chembiochem, 10, 1101, 10.1002/cbic.200900025 Wu, 2002, Antiviral effects of an iminosugar derivative on flavivirus infections, J. Virol., 76, 3596, 10.1128/JVI.76.8.3596-3604.2002 Crabtree, 2005, Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses, Arch. Virol., 150, 771, 10.1007/s00705-004-0430-8 Mackenzie, 1996, Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication, Virology, 220, 232, 10.1006/viro.1996.0307 Muylaert, 1996, Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence, Virology, 222, 159, 10.1006/viro.1996.0406 Tajima, 2008, Characterization of Asn130-to-Ala mutant of dengue type 1 virus NS1 protein, Virus Genes, 36, 323, 10.1007/s11262-008-0211-7 Winkler, 1989, Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization, Virology, 171, 302, 10.1016/0042-6822(89)90544-8 Stein, 2008, Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus, J. Antimicrob. Chemother., 62, 555, 10.1093/jac/dkn221 Lee, 2006, Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses, Antiviral Res., 69, 31, 10.1016/j.antiviral.2005.08.006 Ruddock, 2006, N-glycan processing in ER quality control, J. Cell Sci., 119, 4373, 10.1242/jcs.03225